Skip to main content

Survey Finds Athletes Report Using Cannabis Products To Promote Exercise Recovery

For many years athletes were discouraged from consuming cannabis at all costs. They were often told by their coaches and trainers that cannabis was bad for them, that it was a ‘gateway drug,’ and that it would ruin their athletic aspirations.

These days many athletes openly admit to being cannabis consumers, including elite athletes in professional sports leagues. Those athletes, as well as amateur athletes who consume cannabis, are proving that cannabis can absolutely be a part of an active lifestyle.

A recent study was conducted in the United States that surveyed athletes to gain insight into their cannabis consumption habits. Below is more information about it via a news release from NORML:

Kent, OH: Those who engage in regular exercise frequently report consuming cannabis products to assist in recovering from physical activity, according to data published in the Journal of Cannabis Research.

Researchers affiliated with Kent State University in Ohio surveyed over 100 subjects who reported using cannabis and regularly engaging in aerobic and/or resistance exercise.

Investigators summarized their findings as follows: “Twenty-two participants (20 percent) reported using CBD for recovery from aerobic exercise and 25 participants (23 percent) reported CBD use to recover from resistance exercise. Sixty-eight participants (61 percent) reported using THC after aerobic exercise for recovery. Similarly, 67 participants (60 percent) reported using THC after resistance exercise for recovery. When participants were asked, ‘Do you feel that cannabis in the form of CBD aids in your recovery?’ 93 percent stated ‘yes’ while seven percent stated, ‘I’m not sure.’ When asked, ‘Do you feel that THC aids in your recovery?’, 87 percent of participants stated, ‘yes’ while 13 percent stated, ‘I’m not sure’. No participant answered, ‘no’, for either of these questions. All of the participants felt that use of cannabis was low risk regarding health outcomes.”

The authors concluded: “The present study demonstrated that in addition to more traditional recovery methods, cannabis is used as an ergogenic recovery aid by individuals that exercise regularly. … More data are necessary to understand the role of cannabis in exercise recovery as well as perceived ergogenic benefits of cannabis by individuals who both regularly participate in exercise and habitually use cannabis.”

Another study published in the same journal earlier this year reported that the twice-daily use of topical CBD alleviates chronic pain in former elite-level (professional) athletes.

Several other studies have found that cannabis use is associated with increased exercise frequency, including among older adults. Yet another study, published in July, found that subjects reported “a more positive exercise experience” when they ran immediately after having used cannabis compared to when they did not.

Full text of the study, “Cannabis use for exercise recovery in trained individuals: A survey study,” appears in the Journal of Cannabis Research.

Cannabis Seminary For Doctors And Nurses To Be Held At University Of Ljubljana

Check out the upcoming event at the University of Ljubljana titled ‘Hemp and its Active Ingredients in Healthcare III’ on October 11th and 18th, 2023. The event is co-organized by the Research Nature Institute and is the third education seminary of a series involving doctors and nurses from the faculty at the University of Ljubljana.

The first day of lectures will discuss examples of good practices for nurses and doctors in Slovenia and abroad. Topics will include dosage recommendations, destigmatizing cannabis, and the treatment of neurodevelopmental syndromes.

The second day of presentations will explore potential issues and harm-reduction techniques for consuming cannabis for medical purposes. Attendees will hear for the first time how successful the clinical treatment of multiple sclerosis, Parkinson’s, and Alzheimer’s disease is in Uruguay. Below is the event’s program:

Wednesday, 11/10/2023 – hybrid 

16:00 – 16:05 Welcome address
16:05 – 16:45 Education of health workers on the use of cannabis and cannabinoids for medical purposes: literature review
Jasna Kovač, mag. dr. care, Pediatric Clinic UKC, MEDCA
Tatjana Lončar, B.Sc. med sestra Gynecology Clinic UKC, MEDCA
16:45 – 17:25 US Nurses Journey to Reduce the Stigma of Medical Cannabis ( Maureen Smyth, BSN RN, Certified Cannabis Nurse educator (USA) – ZOOM)
17:25 – 17:35 Break
17 :35 – 18:15 Treatment of neurodevelopmental syndromes with cannabidiol and medical cannabis (Prof. Dr. David Neubauer, MD)
18:15 – 19:00 Dosing – Developing a Cannabis Dose-Effect Hypothesis / “The Dosing Project – developing a Cannabis Dose-Effect Hypothesis« (dr. Jean Talleyrand, MD (USA) – ZOOM))

Research and findings in medicine
Wednesday, 18.10.2023 – hybrid

16:00 – 16:40    Kanabinoidi pri zdravljenju raka, primer glioblastoma (prof. dr. Tamara Lah Turnšek (NIB))
16:40 – 17:20    Problematic Cannabis Use of Medicinal Cannabis (dr. Ilya Reznik, MD – ZOOM)
17:20 – 17:30   Odmor
17:30 -18:10    Can Cannabis treat endometriosis (dr. Lumir Hanuš – ZOOM)
18:10 – 18:50  Therapeutic implications of cannabinoid actions in the brain and neurodegenerative diseases. A clinical perspective in Multiple Sclerosis, Parkinson’s disease, Alzheimer’s disease. (dr. Raquel Peyraube, MD (Urugvaj) – ZOOM)

The event will be moderated by journalist Mr. Gorazd Rečnik, who will lead the discussion and enable the lecturers and guests to ask questions online.

The seminar is intended for the general public, experts, health workers, politicians and officials, who will make future decisions in the field easier with the acquired knowledge.

Lectures will be held in Slovenian and English.

METHOD OF IMPLEMENTATION – hybrid:
– live  at the Faculty of Medicine, Zdravstvena pot 5, Ljubljana  or
– in an online environment.

CO-ORGANIZER : RN, Institute for Nature Research, Development and Quality Assurance of Natural Medicines, with which the Faculty of Health UL has been actively cooperating for many years, is a research and educational institution.

APPLICATION

REGISTRATION

30 EUR with VAT (exclusively for both days).

The content of the education is to obtain points from the ZZBNS and the Medical Chamber of Slovenia.

Participants receive certificates.

For more information about individual lectures and lecturers, write to vesna.osojnik@zf.uni-lj.si, call 01 300 11 65, or go to: https://www.zf.uni-lj.si/si/arhiv-obvestil-cvu/1295-konoplja-in-njene-ucinkovine-v-zdravstvu-iii

Cannabis Extracts Associated With Sustained Chronic Health Condition Improvements

Anyone who has suffered from one or more health conditions knows that it can negatively impact a person’s quality of life. In some cases, one or more health conditions can completely debilitate the suffering patients’ day-to-day existence.

Part of the negative impact on the patient’s life is due to the health condition(s) that the patient is suffering from, however, in many cases that lower quality of life is compounded by the pharmaceutical medication regimen that the patient is tasked with.

Medical cannabis is being used as an alternative to many traditional pharmaceuticals, and a recent study in Australia found that cannabis extracts were associated with sustained improvements in reported quality of life among patients suffering from a range of conditions. Below is more information about it via a news release from NORML:

Sydney, Australia: The use of plant-derived cannabis extracts is associated with health-related quality of life improvements in patients suffering from pain, fatigue, and other chronic conditions, according to observational trial data published in the journal PLOS One.

Australian investigators assessed the efficacy of cannabinoid extracts in a cohort of 2,300+ patients authorized to use medical cannabis. (Under Australian law, physicians may authorize cannabis products to patients unresponsive to conventional prescription treatments.) Study participants consumed extracts containing varying percentages of THC and CBD for three months.

Consistent with the results of other large-scale observational studies, researchers reported clinically meaningful improvements following cannabis treatment.

“This study found [that] overall HRQL [health-related quality of life] improved over 3-months in patients accessing prescribed MC [medicinal cannabis] in Australia,” authors reported. “Results showed both statistically significant and clinically meaningful improvements in overall HRQL and fatigue for people with chronic health conditions. Similar improvements were found in pain scores for participants with chronic pain; depression scores for patients with depression; and anxiety scores in patients with anxiety.”

They concluded: “Our findings suggest that prescribing MC in clinical practice may alleviate symptoms of pain, fatigue, anxiety, and depression in patients with chronic health conditions and improve overall HRQL. … The findings from this study contribute to the ongoing evidence for decision making both in clinical practice and at policy level.”

Full text of the study, “Health-related quality of life in patients accessing medicinal cannabis in Australia: The QUEST initiative results of a 3-month follow-up observational study,” appears in PLOS One.

Vaporized Cannabis Associated With Reduced Symptoms In PTSD Patients

For many years, medical cannabis patients largely consumed cannabis by smoking flower. However, in recent years the different types of cannabis products and consumption methods have increased considerably.

A popular cannabis consumption method among medical patients that is not new is vaporizing flower. Vaporizers such as the Volcano can provide tremendous relief for patients while limiting the amount of inhaled carcinogens.

Researchers in Canada recently conducted a study involving vaporized cannabis and patients diagnosed with post-traumatic stress. Below is more information about the study via a new release from NORML:

Vancouver, Canada: The short-term use of herbal cannabis consisting of a balanced ratio of THC and CBD is associated with symptom reductions in patients with post-traumatic stress, according to data published in the journal Trials.

Canadian researchers assessed subjects’ use of vaporized cannabis over a three-week period.

Investigators reported, “Comparison of CAPS [Clinician Administered PTSD Scale] scores pre and post treatment identified a trend toward reduction in PTSD symptoms. … However, under-recruitment resulted in low power and prohibited placebo comparison, making these results more suggestive than persuasive.”

They concluded, “Positive trending results and high patient need mandate future studies of cannabis for the treatment of PTSD.”

Two recent observational studies, one from Australia and the other from the United Kingdom, reported that patients diagnosed with post-traumatic stress respond favorably to medical cannabis treatment. By contrast, a 2021 clinical trial reported that the inhalation of marijuana flowers provided limited benefits compared to placebo in treating symptoms of PTSD.

Full text of the study, “A small clinical trial of vaporized cannabis for PTSD: Suggestive results and directions for future study,” appears in Trials. Additional information on cannabis and post-traumatic stress is available from NORML’s publicationClinical Applications for Cannabis and Cannabinoids.

Survey Finds That Many Canadian Nurses Don’t Receive Medical Cannabis Training

Humans have consumed cannabis for many centuries. It’s unknown when the first human discovered the therapeutic benefits of the cannabis plant, however, we know that it was at least several thousand years ago.

It wasn’t until the last century that medical cannabis was prohibited, and the negative impact of that prohibition cannot be overstated. In addition to making criminals out of patients, cannabis prohibition also significantly hindered medical cannabis research.

Additionally, cannabis prohibition has created a situation in which medical professionals are woefully uneducated on the topic of cannabis. With so many humans consuming cannabis, there’s no excuse for medical professionals to know little to nothing about the cannabis plant.

A recent survey conducted in Canada highlights the problem, with most participating Canadian nurses indicating that they did not receive any training about medical cannabis. Below is more information about it via a news release from NORML:

Winnipeg, Canada: Fewer than four in ten Canadian nursing students say that they receive information about the use of medical cannabis during their training, according to survey data published in the journal Nurse Education Today.

Over three hundred nursing students participated in the survey. Only 38 percent acknowledged “receiving any education on cannabis in their nursing program.” Over 90 percent of respondents acknowledged that they would feel uncomfortable discussing cannabis with their patients without further educational training.

“Education on both medical and non-medical cannabis is needed to support future nurses addressing cannabis use in their clinical practice,” the study’s authors concluded. “Nursing institutions must implement and evaluate curricula to ensure nursing students are adequately prepared to address cannabis use in their clinical practice and their own fitness to practice.”

Cannabis has been legally available in Canada via a doctor’s authorization since 2001. The Canadian government legalized marijuana products for adults in 2018.

The study’s findings are consistent with those of prior surveys of health professionals in Canada and the United States which report that most doctors and nurses believe that they receive insufficient training with regard to cannabis.

Full text of the study, “Baccalaureate nursing students’ knowledge, attitudes, educational needs, and use of medical and non-medical cannabis at five institutions in Manitoba, Canada: A cross-sectional analysis,” appears in Nurse Education Today.

Cannabis History Is Made In Slovenia At International Event

The International Cannabis Business Conference was held in Bled, Slovenia last week on September 7th and 8th, with a VIP reception held the night before the event. The two-day event was dedicated to emerging international cannabis science and technology.

Among the speakers at the conference, which is part of a series of cannabis events held around the world, was Dr. Metka Paragi, the current Secretary for Health of the Slovenian Prime Minister’s cabinet. Dr. Paragi, a leading international microbiologist, welcomed attendees of the first-ever International Cannabis Business Conference held in Slovenia.

She provided a brief overview of current usage rates in Slovenia, as well as discussed the level of support for policy modernization efforts in the region. Dr. Paragi also provided an update on the current state of cannabis policy and research in Slovenia. It marked the first-ever presentation at an international cannabis conference by a current officeholder at that level of government.

Dr. Metka Paragi International Cannabis Business Conference Bled Slovenia

In addition to Dr. Paragi, presentations at the two-day science and technology conference were made by:

  • Lumír Hanuš – Chief Scientist, Lumir Lab, Asana Bio Group LTD
  • Prof Dr. Tamara Lah Turmšek – Biochemist, Researcher, National Institute of Biology, Ljubljana
  • Peter Homberg – Partner, Dentons, Head of European Cannabis Group
  • Ngaio Bealum – Conference Master of Ceremonies
  • Alex Rogers – CEO & Executive Producer, International Cannabis Business Conference
  • Božidar Radišič – Project Manager and Founder, Research Nature Institute

International Cannabis Business Conference Bled Slovenia

At the conclusion of the event, the International Cannabis Business Conference hosted one of its infamous after-parties, which was headlined by none other than Slovenia’s most famous and loved artist, Magnifico.

Magnifico International Cannabis Business Conference Slovenia 2023

Below are links to media coverage of the event:

Delo

SI21

Dnevnik

RTV Slovenia

24UR

STAznanost

Jutro na Planetu

Make sure to check out the upcoming event at the University of Ljubljana titled ‘Hemp and its Active Ingredients in Healthcare III’ on October 11th and 18th, 2023. The event is co-organized by the Research Nature Institute and is the third education seminary of a series involving doctors and nurses from the faculty at the University of Ljubljana.

To find out more, please visit: https://www.zf.uni-lj.si/si/arhiv-obvestil-cvu/1295-konoplja-in-njene-ucinkovine-v-zdravstvu-iii

Cannabis Extracts Associated With Quality Of Life Improvements In Autism Patients

Emerging cannabis science shows a lot of promise for a number of health conditions that people suffer from, but one that seems to be particularly promising is in the area of cannabis and autism. It’s an area of study that seems to be getting more focus in recent years.

International researchers estimate that as much as 1% of the world’s population has autism, although many patients go undiagnosed for various reasons. A team of researchers in Brazil recently conducted a quality-of-life study focused on autism and cannabis extracts, and the results are encouraging. Below is more information about it via a news release from NORML:

Brasilia, Brazil: Autistic patients who use plant-derived cannabis extracts perceive benefits in their symptoms and reduce their use of prescription medications, according to data published in the journal Frontiers in Psychiatry.

A team of Brazilian researchers assessed the use of individually tailored doses of cannabis extracts in 20 subjects with autism spectrum disorder (ASD). Most patients (80 percent) consumed cannabis extracts for at least six months. Patients used extracts dominant in either CBD or THC. All extracts were administered orally via drops.

Cannabis treatment was associated with perceived symptom improvements as well as with reductions in patients’ use of neuropsychiatric medications. Reported side effects from cannabis treatment were mostly “mild and temporary.”

Investigators reported: “In this manuscript we present the perceived improvements of ASD patients and their families over the course of 3 to 21 months of treatment with FCE [full-spectrum cannabis extracts], using a titration protocol that resulted in personalized CBD and THC dosages, resulting in individually tailored CBD to THC proportions. … Parents reported improvement in all aspects evaluated. Side effects observed during FCE treatment were mild. … As treatment evolved, most other medications had their doses reduced or were completely removed during FCE treatment, which is consistent with the subjective perception of general improvement after FCE treatment. Patients’ and their families’ quality of life improved in 19 out of the 20 cases.”

They concluded: “Our study expands the scientific data demonstrating that clinical use of cannabis extracts is a safe intervention with promising and valuable effects over many core and comorbid aspects of autism that are not achieved by conventional medications. … Based on our findings, we propose guidelines for individually tailored dosage regimens that may be adapted to locally available qualified FCEs and guide further clinical trials.”

Numerous other studies have also identified improvements in autism patients who consume either plant-derived extracts or cannabis flower. Survey data published in 2021 by the publication Autism Parenting Magazine reported that 22 percent of US caregivers or parents have provided CBD to an autistic child.

Full text of the study, “Individually tailored dosage regimen of full-spectrum cannabis extracts for autistic core and comorbid symptoms: A real-life report of multi-symptomatic benefits,” appears in Frontiers in Psychiatry. Additional information on cannabis and ASD is available from NORML’s publicationClinical Applications for Cannabis and Cannabinoids.

Greek Cannabis Study Provides Encouraging News For Patients With Neurological Disorders

Neurological disorders are serious medical conditions that affect the human brain as well as the nerves found throughout the human body and the spinal cord. Examples of neurological disorders include, but are not limited to:

  • Epilepsy
  • Alzheimer disease
  • Multiple sclerosis
  • Parkinson’s disease
  • Brain tumours

Researchers in Greece recently examined the relationship between cannabis and neurological disorders and the results of their research were favorable. Below is more information about it via a news release from NORML:

Athens, Greece: Patients diagnosed with neurological disorders (e.g., epilepsyParkinson’s disease, etc.) experience improvements in their symptoms following medical cannabis treatment, according to data published in the journal Advances in Experimental Medicine and Biology.

A team of Greek scientists assessed cannabis use in a cohort of 100 patients. Patients’ quality of life was assessed via the use of a 36-item health survey.

Researchers reported: “The majority of our patients who received medical cannabis to treat their neurological disorders (58 percent) reported decrease in their symptoms, [including] better energy and vitality … and an improvement in sleeping and appetite after receiving medical cannabis. … Participants, who reported a longer period of receiving medical cannabis, reported statistically significant more energy and vitality, but also better mental and general health status.”

Data published earlier this year similarly reported that the use of plant-derived cannabis oils containing balanced ratios of THC and CBD is safe and effective for older patients suffering from certain treatment-resistant neurological diseases, including Parkinson’s, multiple sclerosis, and peripheral neuropathy.

Full text of the study, “Quality of life in patients receiving medical cannabis,” appears in Advances in Experimental Medicine and Biology. Additional information on the use of cannabis for the treatment of neurological disorders is available from NORML’s publicationClinical Applications for Cannabis and Cannabinoids.

‘Cannabis Light’ Doesn’t Negatively Impact Simulated Driving Performance

‘Cannabis light’ is very popular in many parts of the world right now, particularly in Europe. The term is used to describe cannabis that is low in THC and high in CBD. Many governments around the globe have reformed their laws and/or regulations in recent years to permit cannabis that is low in THC.

The rise in the use of low-THC products has generated questions regarding their safety as it pertains to driving impairment. According to a recent study conducted in Switzerland involving driving simulations, the products do not negatively impact driving performance. Below is more information about it via a news release from NORML:

Basel, Switzerland: The inhalation of high-CBD/low-THC cannabis doesn’t adversely impact driving abilities, according to clinical trial data published in the International Journal of Legal Medicine.

A team of Swiss researchers assessed the impact of CBD-dominant (< 1 percent THC) cannabis on simulated driving abilities.

Consistent with other studies assessing the influence of CBD on psychomotor skills, investigators acknowledged, “No significant differences regarding driving ability were found between the CBD-cannabis products and placebo.”

However, researchers reported that participants nonetheless tested positive for trace levels of THC in their blood in the hours immediately following their use of low-THC herbal cannabis. As a result, they cautioned that some consumers could potentially run afoul of traffic safety laws that impose per se limits for the presence of THC in blood despite having never been impaired.

Five states – Illinois, Montana, Ohio, Pennsylvania, and Washington – impose various per se limits for the detection of trace amounts of THC in blood while ten states (Arizona, Delaware, Georgia, Indiana, Iowa, Michigan, Oklahoma, Rhode Island, Utah, and Wisconsin) impose zero tolerant per se standards. In these states, it is a criminal violation of the traffic safety laws to operate a vehicle with detectable levels of THC in blood – even absent any demonstrable evidence of psychomotor impairment.

NORML has long opposed the imposition of THC per se thresholds for cannabinoids in traffic safety legislation, opining: “The sole presence of THC and/or its metabolites in blood, particularly at low levels, is an inconsistent and largely inappropriate indicator of psychomotor impairment in cannabis consuming subjects. … Lawmakers would be advised to consider alternative legislative approaches to address concerns over DUI cannabis behavior that do not rely solely on the presence of THC or its metabolites in blood or urine as determinants of guilt in a court of law. Otherwise, the imposition of traffic safety laws may inadvertently become a criminal mechanism for law enforcement and prosecutors to punish those who have engaged in legally protected behavior and who have not posed any actionable traffic safety threat.”

Full text of the study, “Effect of vaporizing cannabis rich in cannabidiol on cannabinoid levels in blood and on driving ability – A randomized clinical trial,” appears in the International Journal of Legal Medicine. Additional information is available from the NORML Fact Sheet, ‘Marijuana and Psychomotor Performance.’